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ABSTRACT 
 
Commercially available amphotericin B (AmB) formulations are limited either 
by cytotoxicities, lower efficacies, shelf-life related issues or high production costs. 
AmB complexes based on poly(gamma-glutamic acid) (PGGA) have been prepared and 
evaluated for their efficacies against AmB-deoxycholate (Fungizone®) and liposomal 
AmB (AmBisome®). Physical characterizations showed that AmB/PGGA complexes 
are nanoscopic (20-40 nm) with a negative zetapotential (-51.0 mV), water-soluble, 
stable in solution (up to 4 weeks, at 4°C and 25°C), and have a theoretical drug loading 
(up to 76.9%). In-vitro, AmB/PGGA complexes exhibited an improved and comparable 
cytotoxicity profile as compared with Fungizone® and AmBisome® respectively, with 
respect to haemolytic activity and up-regulation of cytokine productions (TNF-α and 
IL-1ß). AmB/PGGA complexes were significantly more efficacious in-vivo than both 
Fungizone® and AmBisome® in experimental murine candidiasis.  These results 
provide strong evidence that AmB/PGGA complexes have a better efficacy and safety 
profile than the currently approved AmB products. 
 
Abbreviations: AmB = amphotericin B, DLS = Dynamic Light Scattering, TEM = 
Transmission Electron Microscopy, MW = Molecular Weight. 
Key words: amphotericin B, poly(gamma-glutamic acid), AmB/PGGA complexes, 
Fungizone® and AmBisome®, toxicity. 
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INTRODUCTION 
Despite its reported toxicity, the polyene antibiotic, amphotericin B (AmB), has 
found clinical applications in the treatment of systemic fungal infections in patients 
with cancer, AIDS, organ transplantation, and in parasitic disease [1].  Long term 
treatment with a conventional AmB therapy such as Fungizone® (from here on simply 
stated as Fungizone), is associated with high incidence of renal impairment and 
hepatotoxicity [2], [3]. The lipid-based formulations, Amphocil® (colloidal dispersion) 
AmBisome® (liposomes; from here on simply stated as AmBisome) and Abelcet® (lipid 
complex) are more tolerable, offer better protection against the renal damage than 
Fungizone and can be administered at a higher dosage in cases of severe systemic 
infections [4], [5].  AmBisome could be administered up to 3-5 mg/kg daily with lower 
incidences of nephrotoxicity as compared with Fungizone, which is only licensed for a 
daily dose of 1mg/kg [6], [7]. Although less nephrotoxic, the lipid-based AmB 
formulations are less efficacious than the conventional AmB formulations, meaning 
that higher doses are often required for desirable therapeutic effect which may 
subsequently lead to toxic manifestations [8].   
AmB’s inherent low aqueous solubility poses many hurdles in the development 
of a suitable oral or injectable formulation. Both passive and active targeting 
approaches have been employed for delivering AmB. Passive delivery of AmB can be 
achieved using various polymeric systems, which being particulate in nature, are avidly 
taken up by macrophages due to their scavenging property [9]. A plethora of reports 
have shown that the polymeric nanoparticles are readily phagocytosed by macrophages 
[10], [11], [12] leading to the passive accumulation of the drug in the liver and spleen 
(macrophage rich organs). Interestingly, macrophage uptake could be further enhanced 
by attaching target specific ligands onto the nanoparticles [13]. Few examples of these 
actively targeting AmB nanocarriers include the pH-sensitive conjugates of AmB-
poly(ethylene glycol) which selectively releases AmB at target site [14], mannan or 
pullanan bearing liposomes loaded with AmB to target alveolar macrophages [15], and 
a mannose-coated lipid nanospheres of AmB for specific targeting to reticlulo-
endothelial macrophages [16]. 
Several polymeric micelles based on diblock and triblock co-polymers [17], 
[18], [19] have the potential to solubilise AmB.  However, micelles have the tendency 
to lose their integrity in serum mimicking conditions [20], [21], resulting in sudden 
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release, or burst, of drugs in an uncontrolled fashion [20], [22]. An additional issue is 
that the encapsulation in the polymeric micelles resulted in the decrease of in vitro 
antifungal activity of the drug [23], [17]. Other polymers such as polyvinyl-pyrrolidone 
possess the ability to complex AmB, but suffer from very low (0.249% w/w) AmB 
loading [24]. AmB–cyclodextrin complexes have shown improved water solubility [25] 
but demonstrate toxicity to human red blood cells [26].  
Biocompatible and water-soluble polymers, both synthetic and naturally-
occurring, have been extensively used to improve water solubility, optimise 
pharmacokinetics and improve drug efficacy and safety [27]. The naturally-occuring 
poly(gamma-glutamic acid) (PGGA) is known to be biodegradable, non-toxic, non-
immunogenic [28], well-tolerated at high doses in preclinical studies [29], and 
importantly is chemically modifiable owing to the presence of the pendant carboxylic 
groups [30]. PGGA can be obtained in large amounts at low production costs through 
engineering and optimization of various microbial fermentation processes [31].  Herein, 
we describe the development and evaluation of alternative AmB formulations using 
PGGA as the delivery vehicle. Through physicochemical and biological 
characterizations, we have been able to confirm that the as-synthesized AmB/PGGA 
complexes have a better safety profile as compared to Fungizone in vitro, and greater 
antifungal efficacy than both Fungizone and Ambisome in vivo.  The data suggests that 
by employing a non-covalently associated polymeric nanocarrier, it is possible to 
overcome problems associated with delivering a potent but highly cytotoxic and 
hydrophobic drug such as AmB. 
 
MATERIALS AND METHODS 
AmB/PGGA complex synthesis 
Degradation of high molecular weight PGGA 
In a typical alkaline hydrolysis reaction, PGGA of the free acid form (5 g, 34.45 
mmol; 1500 kDa, Natto Biosciences) was dissolved in aqueous sodium bicarbonate (50 
mL, 67.60 mM). The solution was heated to 90°C and NaOH (1.38 g, 34.45 mmol) was 
added. The solution was maintained at 90°C for 6 h, and then was left to cool to room 
temperature. The pH of the solution was adjusted to 7.0 with HCl, and subsequently 
treated with Amberlite resin (50 g, IR-120 H+ type, 50 mesh Sigma-Aldrich). After 1 
h, the Amberlite resin was separated from the mixture by filtration and washed with 
deionised water (50 mL). The filtrate was collected and kept at 2-8°C for 2 days prior 
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to further filtration to facilitate the precipitation of the polymer. The precipitate was 
collected and excess water was removed from the precipitate by freeze-drying. 
Molecular weight (MW) determination was carried out by Gel permeation 
chromatography (GPC), while the purity of the sample was assessed by FT-IR. 
 
N-Hydroxysuccinimide (NHS) activation of PGGA 
In a typical reaction, degraded PGGA (5 g, 34.45 mmol) and NHS (1.98 g, 17.23 
mmol, Sigma-Aldrich) were dissolved together in anhydrous DMSO (30 mL). NHS 
activation of PGGA was initiated by the drop wise addition of N, N′-
diisopropylcarbodiimide (DIPC) (2.63 mL, 17.23 mmol, Sigma-Aldrich) at room 
temperature. After 20 h, the reaction was terminated and the reaction mixture was stored 
at 2-8°C for 24 h. Activated polymer was precipitated out in dehydrated acetone, and 
the precipitate was treated twice with ice-cold dehydrated acetone and once with 
dehydrated hexane. Dehydration of acetone and hexane was carried out by treatment 
with molecular sieve beads (3A type, 4-8 mm, Sigma-Aldrich). The precipitate was 
collected and dried under vacuum. The NHS content was determined by 1H-NMR 
spectroscopy using a Bruker Advance spectrometer 
 
Preparation of AmB/PGGA complexes 
In a typical complex preparation, NHS-activated PGGA (10 mg, 68.9 mmol; 
solubilised in DMSO (200 μL)) was added drop-wise to the AmB solution (7.0 mg, 
7.47 mmol, Sigma-Aldrich; solubilised in 200 μL of DMSO) in a round bottom flask 
with stirring over 15 min. Sodium hydroxide (109 μL, 109 mmol) was added drop-wise 
to the reaction mixture, followed by water (1 mL), and the mixture was left to stir for 
1 h at room temperature.  After further dilution with water (3.5 mL), the resulting 
solution was purified by dialysis (Visking, MW cut-off 12,000 -14,000 kDa) against 
deionised water over 24 h. Finally, the dialysate was passed through a 0.2 μm filter 
(Millipore) before lyophilisation.   
 
Characterisation of degraded PGGA and NHS-activated PGGA 
Molecular weight (MW) of degraded PGGA was determined by Gel Permeation 
Chromatography (GPC)   using a Viscotek Trisec Dual Detector Model 270 based on 
methacrylic salt 10,300 Da as a standard.  Physicochemical properties of degraded 
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PGGA were compared against the parent PGGA by Fourier Transmission Infra-Red 
(FT-IR) spectroscopy using a Perkin Elmer Spectrum 100 FTIR spectrometer; data 
were processed using Spectrum Express V.1.2.0 software. NHS-activated PGGA was 
analysed for its NHS content by 1H-NMR spectroscopy using a Bruker Advance 
spectrometer operating at a nominal 1H frequency of 400 MHz and equipped with a 6 
mm BBO probe inducing Z-axis pulse field gradients. Spectra were processed using 
TOPSPIN 1.3 software. 
 
Characterisation of AmB/PGGA complex 
Drug loading efficiency and aggregation state of AmB were ascertained by UV-
Vis spectroscopy. TEM analysis was performed to analyse size and shape of the 
complex. The hydrodynamic particle size and zeta potential of the AmB/PGGA 
complexes were determined by Dynamic Light Scattering (DLS) technique using a 
Zetasizer Nano ZS instrument (Malvern). Interactions between PGGA and AmB were 
analysed by HPLC using an Agilent Zorbax SB-C18 analytical column. 
 
Stability of AmB/PGGA complexes in solution 
The effect of storage conditions on the stability of AmB/PGGA complexes in 
solution after reconstitution in water was assessed over a 4-week period at 2-8° and 
room 25°C. 
 
In-vitro antifungal activity of AmB/PGGA complexes 
Antifungal activities of the AmB/PGGA complexes were evaluated by Minimal 
Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) 
determinations, according to the guidelines by the Subcommittee on Antifungal 
Susceptibility Testing of the NCCLS. 
 
Haemolysis assay 
Preliminarily, acute drug toxicity was assessed through in vitro erythrocyte lysis 
test, wherein hemoglobin released as a result of membrane leakage or disruption caused 
by exposure to the drug formulation was measured. 
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Modulation of pro-inflammatory cytokines 
PBMC were incubated with test samples (AmB/PGGA complexes of 55 kDa 
and 110 kDa, Fungizone and AmBisome) at various concentrations for 24 h at 37°C 
and 5% CO2. After incubation for 24 h, the supernatants were collected and 
immunoassayed for the determination of the cytokines TNF-α and IL-1β using 
immunoassay kits Human TNF-α and IL-1β ELISA Ready-SET Go (eBioscience). 
 
Assessment of antifungal efficacy in vivo 
The antifungal efficacies of various AmB formulations were assessed by 
monitoring the survival of the infected animals and determining the clearance of C. 
albicans from various vital organs viz. liver, spleen and kidney. In each experiment, the 
infected animals were divided in 7 different groups with each group comprising of 20 
animals. The animals were administered with the control (PBS), or polymer (PGGA 55 
kDa and PGGA 110 kDa), or a single dose of 5 mg/kg body weight of various AmB 
formulations via the subcutaneous route [Fungizone, AmBisome, AmB/PGGA 
complex (55 kDa), AmB/PGGA complex (110 kDa)]. For survival studies, the 
mortality of the animals was observed twice each day during 50 days of observation. 
Antifungal treatment was begun 24 h after challenge of animals with C. albicans 
infection. Two animals from each group were sacrificed on day 7, 15 and 21 post-
infection and pathogen burden was ascertained in vital organs. 
Statistical analysis: data were analyzed by the Student’s t-test and one way analysis of 
variance (Holm-Sidak method), using Sigma-Plot version 10 software. P-values <0.05 
were considered to be statistically significant. 
 
Supplementary section:  Please refer to the Supplement for more details on Materials 
and Methods, physicochemical characterisations, cytotoxicity and in vitro antifungal 
evaluations, as well as additional figures. 
 
RESULTS 
Degradation of PGGA 
Molecular weight determination by Gel Permeation Chromatography (GPC): 
The results of PGGA degradation are shown in Table 1. For the determination of 
molecular weight (MW) of the PGGA, the  specific refractive index (dn/dc) of the 
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polymer was obtained from a plot of refractive index (IR) detector peak area versus the 
PGGA concentration (0 – 10 mg/mL) at a fixed volume (1 mL); the slope of which 
corresponded to the dn/dc value (0.0939) (Figure S1). The polymer MW was calculated 
using the Rayleigh equation:  
 
Where R, K, C and M are the intensity of the scattered light, the optical constant, 
the concentration and MW of the polymer, respectively.  
 
Table 1. Molecular weight reduction of PGGA Starting polymer MW = 1500 kDa. Data are pooled 
from three separate experiments (N=3). 
 
Analysis of degraded PGGA by FT-IR: Figure 1 shows the FT-IR spectra of the 
parent and degraded PGGA polymers, which are identical, except the parent PGGA 
produces higher intensity bands. The FT-IR spectra show a band at 3271.50 cm-1 which 
is characteristic of the N-H stretch, whilst a band that is indicative of the COOH group 
appears at 1446.06 cm-1. In addition, the absence of additional peaks suggests that the 
degraded PGGA was of high purity.  
 
Figure 1. FT-IR spectra of the parent and degraded PGGA.  Parent PGGA (red bottom line) and 
degraded PGGA (other lines). The main peaks are N-H (3271.50 cm-1) and COOH (1446.06 cm-1). 
 
N-Hydroxysuccinimide (NHS) activation of PGGA 
Determination of NHS activation: The extent of NHS activation was determined 
using 1H-NMR.  Figure S2B shows an example of a 1H-NMR spectrum of NHS-
activated PGGA.  The peak at 2.8 ppm corresponds to the protons of NHS; this peak is 
present in the final product in contrast to that of the starting polymer (Figure S2A), and 
is further downfield compared to the reference NHS peak (2.6 ppm, not shown) 
indicating that the NHS moiety is now coupled to the polymer. In addition, the proton 
which corresponds to the α-carbon now appears downfield (4.15 ppm to 4.64 ppm), 
which provides further evidence that the NHS has coupled to PGGA. Using varying 
amounts of reactants, it was possible to achieve up to 91% of NHS substitution (Table 
2). 
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Table 2. NHS activation of PGGA.  The degree of NHS activation was estimated by 1H-NMR. Data 
are means of triplicates ± SD (N=3). 
 
 
Characterisation of AmB/PGGA complex 
AmB theoretical and practical loading efficiencies of AmB/PGGA complexes 
are between 69.9-76.9% and 29.5-34.7%, respectively (Table 3). The complex appears 
spherical in structure (Figure 2A) and the particle size is distributed between 20-40 nm 
in diameter (TEM (JEOL), magnification x 135000 at 120 kV). Figures 2B and 2C show 
the size and zeta potential of a sample complex in solution. The hydrodynamic diameter 
of the AmB/PGGA complexes (55, 65 and 110 kDa) ranges between 96.3 – 122.5 nm 
with a zeta potential between -45.5 to -51.0 mV (Table 3). 
 
Figure 2. Size and shape characterization of AmB/PGGA complex: (A) Morphology of by TEM; 
(B) Size and (C) zetapotential by DLS.  
 
Table 3. Drug loading efficiency; size and zeta potential of AmB/PGGA complexes by DLS. Data 
are means of triplicates ± SD (N=3). 
 
 
UV Spectroscopy Analysis 
The UV spectra of the AmB/PGGA complex, Fungizone and AmBisome are 
shown in Figure 3. In Fungizone, AmB exists predominantly as oligomeric aggregated 
species with a maximum absorption at 328 nm, whereas in the AmB/PGGA complex 
and AmBisome, AmB exists mostly as superaggregates with a maximum absorption at 
322 nm. 
 
Figure 3.UV spectra of AmB/PGGA complex, Fungizone and AmBisome. 
 
Stability of AmB/PGGA complexes in solution 
The stability of AmB/PGGA complexes in solution after reconstitution in water 
was assessed over a 4-week period at refrigerated (2-8°) and room (25°C) temperatures 
(Table 4). After 1 week, ≥98% AmB was retained within the both complexes at both 
temperatures. After 4 weeks, ≥91% AmB was found to remain associated with the 
polymer. In fact, both samples remained stable for 3 weeks when stored at 2-8°C whilst 
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solutions stored at 25°C lost >10% of AmB content by week 4. The data suggests that 
the stability of the complex is greater at 2-8°C. 
 
Table 4. Size distribution of AmB/PGGA complexes and % AmB retained in complex at week 
0,1,2,3 and 4 at 4°C and 25°C. Data are means of triplicates ± SD (N=3). 
 
Analysis of interaction between AmB and PGGA by HPLC 
Figure S3 shows the elution times for AmB/PGGA and AmB which are 10.2 
and 10.19 min, respectively. The HPLC column used was a reverse phase hydrophobic 
affinity column (Agilent Zorbax SB-C18). The near identical elution times for 
AmB/PGGA and AmB suggest that the PGGA carrier did not affect the interaction 
between the AmB molecule of the AmB/PGGA complex and the HPLC column. 
 
Haemolysis assays 
Haemolytic activity of AmB/PGGA complexes, AmBisome and Fungizone 
were evaluated at 1 and 24 h as shown in Figure 4A and Figure 4A respectively. 
Haemolysis was found to be AmB concentration-dependent, with Fungizone having the 
highest haemolytic activity, followed by AmB/PGGA complexes (with the lower 
polymer MW causing the higher haemolysis) and AmBisome, for both 1 and 24 h 
assays.  Haemolysis was determined at time t = 1 and 24 h, expressed as % haemolysis 
at λ = 580 nm. 
 
Figure 4. Haemolytic activity of AmB/PGGA complexes, AmBisome and Fungizone after (A) 1 h 
and (B) 24 h of incubation with human red blood cells. Data are means of triplicates ± SD (N = 3). 
 
Evaluation of in vitro antifungal activity 
The antifungal activity of AmB formulations was evaluated by performing MIC 
and MFC determinations at the AmB concentration range of 0.03-16 μg/mL (original 
conc. = 32 μg/mL) with an inoculum size of ~1 x 104 CFU. Table 5 shows the MICs 
and MFCs at 24 and 48 h; and 48 h, respectively. Overall, MIC and MFC values of all 
AmB/PGGA complexes, Fungizone and AmBisome were consistently equal or one-
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fold dilution higher or lower than those recorded for AmB. PGGA alone had no 
antifungal activity.  
Table 5. MICs and MFCs of AmB/PGGA complexes, Fungizone, AmBisome and AmB against 
Candida spp., expressed as (μg/mL). Data are modal values of 3 independent measurements. Range 
varied no more than two-fold from stated values in each case.  
 
Modulation of pro-inflammatory cytokine production 
Regulation of the cytokines TNF-α and IL-1β was evaluated for AmB/PGGA 
complexes against the comparators, AmBisome and Fungizone (Figures 5A and 5B). 
There were no significant differences between the formulations except for Fungizone, 
which caused the highest upregulation for both cytokines at the highest AmB 
concentration tested (2 μg/mL). 
 
Figure 5. Cytokine release as a function of AmB concentration, produced by PBMCs in the 
presence of various AmB formulations: (A) TNF-α; (B) IL-1β. Data are means of triplicates (N=3). 
 
Evaluation of in vivo antifungal efficacy 
The efficacy of AmB/PGGA complexes was evaluated in mice infected with C. 
albicans and were compared against Fungizone and AmBisome, with PBS as a control. 
Figure 6 shows that both AmB/PGGA C55 kDa and C110 kDa complexes were 
significantly more efficacious, as compared with Fungizone and AmBisome [C55 kDa 
and C110 kDa complexes versus Fungizone (p<0.001) and AmBisome (p<0.001)]; and 
C110 kDa was significantly more efficacious than C55 kDa (p<0.001).  Assessments 
of fungal load in vital organs (spleen, liver and kidneys) after treatment with AmB 
formulations also confirmed that overall, AmB/PGGA complexes were more 
efficacious than Fungizone and AmBisome, with the higher MW complex having the 
greater efficacy (Figures 7A, 7B, and 7C). 
 
Figure 6. Survival percentage of animals infected with C. albicans cells (107 CFU) over 50 days 
post-treatment (PGGA 55 kDa = PGGA polymer of MW 55k Da alone, PGGA 110 kDa = PGGA 
polymer of MW 110 kDa alone, C 55 kDa = AmB/PGGA complex with MW 55 kDa, C 110 kDa = 
AmB/PGGA complex with MW 110 kDa). 
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Figure 7. Assessment of fungal load in vital organs of infected animals; (A) spleen (B) liver and (C) 
kidney (PGGA 55 kDa = PGGA polymer of MW 55k Da alone, PGGA 110 kDa = PGGA polymer 
of MW 110 kDa alone, C 55 kDa = AmB/PGGA complex with MW 55 kDa, C 110 kDa = 
AmB/PGGA complex with MW 110 kDa). 
 
 
DISCUSSION 
Our goal was to develop an alternative AmB formulation that offers the best 
attributes of the approved AmB formulations, namely the high efficacy and low cost of 
the AmB-deoxycholate, along with improved safety profiles of the lipid based AmB 
formulations. Using the naturally-occurring and biodegradable polymer PGGA, we 
were able to synthesize non-covalently associated AmB/PGGA complexes of varying 
polymer molecular weights (55, 65 and 110 kDa). The preparation of the AmB/PGGA 
complexes involved three main processes: firstly, the MW reduction of the high MW 
PGGA by alkaline hydrolysis; secondly, the hydrophobisation of the reduced PGGA 
via NHS activation to increase its organic solubility; and thirdly the preparation of 
complexes through solubilisation of drug and polymer in an organic medium (DMSO), 
followed by alkaline hydrolysis. Using varying amounts of reactants, it was possible to 
achieve lower MW polymer (Table 1), with high purity as shown by F-TIR (Figure 1); 
and up to 91% of NHS substitution (Table 2). As the drug and polymer underwent 
alkaline hydrolysis and transitioned from an organic medium to a predominantly 
aqueous medium, it was observed that the water-soluble AmB/PGGA complexes 
formed spontaneously, possibly via a mechanism of self-assembly. Although we did 
not verify this, PGGA or its derivatives have been known to form self-assembled, nano-
sized particles [32]. Several researchers have demonstrated the self-assembly formation 
of nano-carriers based on PGGA [33], [34]; with one recent study confirming the self-
assemblage of PGGA nanoparticle by measuring CMC (critical micelle concentration) 
using pyrene as a hydrophobic probe [35]. In general, polymeric nanoparticles are often 
formed through self-assembly [36], a process driven by the hydrophobic, hydrophilic 
and amphiphilic characteristics of the different (co)polymers. In contrast to conjugation 
methods, which often requires complex coupling chemistry, our method is 
comparatively simpler and highly efficient, achieving a consistent practical loading of 
26.1 to 34.7% (w/w) (Table 3), which compares well against 3.8% (w/w) and 45.5% 
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(w/w) for AmBisome and Fungizone, respectively. The data suggests that AmB/PGGA 
complexes can be formulated using only PGGA and no other excipients; this is an 
advantage over products that require many stabilising agents, since these excipients 
may cause toxicity and/ or incompatibility issues [37]. 
Lyophilised AmB/PGGA complexes were found to be readily soluble in water, 
resulting in a clear solution.  In contrast, the reconstitution of both AmBisome and 
Fungizone involves a more complicated procedure that requires vigorous shaking, 
inspection or dilution [6], [7].  TEM imaging of the AmB/PGGA complexes revealed a 
uniform population of spherical nanoparticles with a mean diameter of 20-40 nm 
(Figure 2). The morphology of the complexes is similar to that reported by Yoo et al. 
which, according to the author, is indicative of a polymeric micellar system [38]. It was 
hypothesised that the interaction between the carrier (PGGA) and the drug (AmB) was 
likely to be of a non-covalent nature. To test this hypothesis, the AmB/PGGA complex 
and the free AmB were analysed by HPLC using a hydrophobic column. As shown in 
Figure S3, the elution times were similar between the AmB/PGGA complex and the 
free AmB, indicating that the interactions of AmB in the complex with a hydrophobic 
affinity column were therefore not affected by the forces that hold the polymeric carrier 
(PGGA) and AmB together.  This suggests that the interactions between the PGGA and 
AmB were non-covalent rather than covalent because the latter would have affected the 
elution time of the AmB/PGGA complex. 
Non-covalent complexes are known to suffer from the possible risk of drug loss 
from the drug carrier due to the weaker forces that hold the drug and the drug carrier as 
compared with a covalent drug-conjugate.  We, therefore, investigated the stability of 
the AmB/PGGA complexes (55 and 110 kDa) in solution and found that both 
AmB/PGGA complexes retained more than 90% of AmB at 4°C, and more than 86% 
of AmB at 25°C, after 4 weeks (Table 4). The apparent high stability of the AmB/PGGA 
in solution could be due to the negative charge and the nanoscopic range of the 
complexes (∼-50 mV, and 90 – 120 nm as measured by DLS, respectively) (Table 3). 
Previous studies have reported that small and negatively charged particles have high 
stability, reduced interactions with blood components, as well as greater passive 
targeting and longer blood residence time [39], [40]. Extremely positive or negative 
zeta potential values cause larger repulsive forces; this repulsion between similarly 
charged particles prevents aggregation of the particles and thus maintains a stable 
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system [41]. Polymeric systems, such as the AmB/PGGA complexes, are characterised 
by greater thermodynamic stability, as evidenced by their lower CMCs than smaller 
surfactants, thereby offering high resistance to dissociation [42]. On the contrary, as per 
label, Fungizone should be stored for no more than 8 hours at room temperature (25°C) 
or 24 hours in a refrigerator (2-8°C), and the in-use storage time of AmBisome would 
normally not be longer than 24 h at 2-8°C [6], [7].  A study assessing the stability of 
Fungizone solutions has reported up to 20% loss of AmB after 1 h incubation at 37°C 
due to auto-oxidation processes and colloidal instability [43], [44].   
AmB is known to interact freely with the cholesterol in red blood cells leading 
to severe haemolysis [45], [46].  Haemolysis assays at 1 and 24 hours demonstrated that 
all three AmB/PGGA complexes caused significantly less haemolysis than Fungizone 
but greater than AmBisome, and the AmB/PGGA complex with the higher MW 
polymer to be less haemolytic (110 kDa< 65 kDa<55 kDa) (Figure 4). Fungizone is 
highly haemolytic because it is formulated with the excipient, sodium deoxycholate, an 
anionic surfactant known to cause haemolysis [58]. Previously, low haemolytic activity 
has been attributed to the superaggregated form of AmB, found in AmBisome and in 
the heated solution of Fungizone; as indicated by a UV spectral shift of the maximum 
absorption from 328 nm to 322 nm [43].  Figure 3 confirms that AmB/PGGA complex 
too contains the superaggregated form of AmB, which is in accordance with a study 
conducted on a AmB formulation developed with a variant of PGA (poly L-glutamic 
acid) [46], and thus provides an explanation for the observed lowered haemolytic 
activity of the AmB/PGGA complexes. It has been suggested that the regulated release 
of AmB from the polymer maintains the released drug in a monomeric form (since the 
concentration of the released drug remains below its CMC for aggregation), preventing 
it from forming oligomeric aggregates. Both monomer and super-aggregate forms of 
AmB are less toxic, while the oligomeric species are mainly responsible for the drug 
induced toxicity [47]. Moreover, only small amount of drug is available to bind to the 
red blood cell membrane due to the slow release, thereby reducing toxicity; although 
this is yet to be tested experimentally. 
The formulation process of the AmB/PGGA complexes did not affect the AmB 
structure, as evidenced by the antifungal efficacy of the AmB/PGGA complexes in vitro 
against Candida albicans ATCC 14053 and Candida tropicalis ATCC 750 and 
demonstrated similar efficacy as compared with Fungizone and AmBisome.  The MFC 
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values of the AmB/PGGA complexes were also comparable to those of Fungizone and 
AmBisome (0.5-1 μg/mL) (Table 5).  
The administration of conventional AmB is often associated with infusion-
related toxicity side effects such as fever and chills, as a result of the upregulation of 
proinflammatory cytokines, TNF-α and IL-1β [48], [49].  In human peripheral blood 
mononuclear cells (PBMCs), it was found that Fungizone upregulated the production 
of both TNF-α and IL-1β, whereas the two AmB/PGGA complexes (55 and 110 kDa) 
and AmBisome did not (Figure 5).  These findings also indirectly confirm clinical 
experience which reports greater incidence rates of infusion-related toxicity for 
Fungizone than AmBisome [48]. Based on these findings, it is reasonable to expect that 
AmB/PGGA complexes may have similar incidence rates of the aforementioned 
toxicity as with AmBisome.  
The antifungal efficacy of two AmB/PGGA complexes  was evaluated in 
experimental murine candidiasis.  AmB/PGGA complexes were found to be more 
effective in clearing fungal burden in liver, spleen and kidney of infected animals than 
both Fungizone and AmBisome (Figure 7). The greater antifungal efficacies of the 
AmB/PGGA complexes were further established in our survival studies in which the 
AmB/PGGA complexes out-performed both Fungizone and AmBisome by a significant 
margin. Fifty days post treatment, the survival rates for the animals receiving the 
AmB/PGGA complex (110 kDa), the AmB/PGGA complex (55 kDa), AmBisome and 
Fungizone were 80%, 50%, 30% and 0%, respectively (Figure 6). Our data suggest that 
the AmB/PGGA complexes have a higher antifungal efficacy than both comparators.    
The mechanism by which the AmB/PGGA complexes exert their greater 
antifungal efficacy is not known, although it has been suggested that the incorporation 
of PGGA into chitosan/siRNA and chitosan/DNA complexes enhances their cellular 
uptake and facilitates the unpacking of the complexes to release the payload upon cell 
entry [50], [51]. It has also been reported that necrotizing vasculitis occurs during 
Candida infections [52] and the leaky blood vessels at these sites of inflammation may 
result in enhanced permeation of nanocarriers [53]. Overall, colloidal polymeric 
carriers including PGGA [10], [11], [12], are naturally passively targeted to, or can be 
tailored to actively target, organs of reticuloendothelial system (RES); leading to 
greater distribution of AmB to liver and spleen, thereby effectively reducing the 
pathogen burden [16]. Biodistribution studies have shown that (passively targeted) 
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Amphocil® and Abelcet® are rapidly accumulated in the mononuclear phagocyte system 
[54]. Incidentally, macrophages are heavily involved in inflammation and pathogenesis 
of many diseases such as candidiasis [55]; thus may act as ‘Trojan horses’ [56] and 
carry encapsulated nanoparticles to the site of infection. Subsequently, nanoparticle-
bearing macrophages may act as ‘secondary depot’ or ‘cellular drug reservoirs’ of 
active drug entities [57], gradually releasing it into the surrounding milieu [58]. Thus, 
macrophages may provide an indirect boost to microbial clearance as the drug can be 
delivered to the site of active pathogen growth [59]. Although initially demonstrated in 
cancer, this paradigm may be extended to other nano-encapsulated therapeutics and 
non-cancer disease indications [60] in which macrophages accumulate near the target 
tissue. It seems, therefore, plausible that PGGA, in a fashion similar to other polymeric 
nanocarriers, facilitate the passive targeting of AmB via macrophages to the site of 
infection; this may explain the enhanced antifungal efficacy (Figure 6 and 7) as well as 
the reduced toxicity of the AmB/PGGA complexes (Figure 4 and 5).  
In conclusion, we have developed AmB/PGGA complexes that possess the 
potential to replace the current commercial AmB formulations. These AmB/PGGA 
complexes have demonstrated a number of desirable attributes including water 
solubility, stability, decreased cytotoxicity and improved antifungal efficiency.  The 
relative simple formulation method and the abundance of the naturally-occurring 
polymer mean that if successfully realised as a medicinal product, an AmB/PGGA 
complex formulation could potentially be manufactured and offered at a low cost.  
However, although PGGA has been consumed by humans over many centuries, it is 
still not known whether it would elicit immunogenicity when administered parenterally. 
Future studies therefore should assess the immunogenicity potential of the AmB/PGGA 
complexes and confirm the enhanced efficacy that was observed in our animal models. 
In our investigations, the AmB/PGGA complex with the higher molecular weight 
polymer performed better than that with lower molecular weight in terms of 
cytotoxicity and antifungal efficacy. It is thus recommended that the higher molecular 
weight AmB/PGGA complexes be further investigated. 
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